LAURUS LABS LIMITED

• Antibody-drug conjugates (ADCs) are gaining traction in APAC, marked by significant investments and collaborations, particularly from Chinese companies, signaling strong potential in targeted cancer therapies. • Cell and gene therapies (CGTs) are experiencing a surge in APAC, with China leading in CAR-T clinical trials and approvals, indicating a growing focus on innovative treatments for oncology and other diseases. • Artificial intelligence (AI) is becoming integral in APAC's pharmaceutical sector, enhancing drug discovery, clinical trials, and personalized medicine, with AI-designed drugs nearing regulatory approval. • The APAC region is solidifying its dominance in clinical trials, driven by a large patient population and regulatory reforms, particularly in oncology, attracting both local and global pharmaceutical firms.